New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:12 EDTCYTXCytori announces publication of Cytori Cell Therapy trial outcomes
Cytori Therapeutics announced publication of safety and efficacy data from a 36 month European clinical trial of Cytori Cell Therapy in patients with chronic ischemic heart failure. Final data from the Companyís PRECISE trial, a 27-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial , or Phase I/IIA, demonstrated statistically significant differences in cardiac functional capacity between treated and placebo groups and will appear in an upcoming issue of the American Heart Journal. Cytori Cell Therapy is a mixed population of adipose derived regenerative cells extracted from a patientís own adipose tissue using Cytoriís proprietary Celution System. Cytori is currently enrolling patients in the U.S. ATHENA and ATHENA II trials, both 45 patient prospective, randomized, double-blind, placebo-controlled trials investigating a lower and a higher dose, respectively, of Cytori Cell Therapy in a similar patient population as PRECISE. In addition, Cytori has received a CE Mark for the Intravase reagent to be used with the Celution System for intravascular delivery. The Intravase CE Mark allows for targeted sales to physicians conducting independent research for intravascular indications.
News For CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
11:55 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
January 22, 2015
11:27 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
January 20, 2015
16:25 EDTCYTXCytori says STAR trial will begin enrolling in 2015
Subscribe for More Information
08:40 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use